Market capitalization | $12.08m |
Enterprise Value | $5.96m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
P/B ratio (TTM) P/B ratio | 2.45 |
Revenue (TTM) Revenue | $0.00 |
EBIT (operating result TTM) EBIT | $-29.98m |
Free Cash Flow (TTM) Free Cash Flow | $-23.75m |
Cash position | $5.79m |
As a Free StocksGuide user, you can view scores for all 6,821 stocks worldwide.
1 Analyst has issued a forecast BriaCell Therapeutics Corp:
1 Analyst has issued a forecast BriaCell Therapeutics Corp:
Oct '24 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | -0.11 -0.11 |
450%
450%
|
|
EBITDA | -30 -30 |
13%
13%
|
EBIT (Operating Income) EBIT | -30 -30 |
14%
14%
|
Net Profit | -17 -17 |
26%
26%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
BriaCell Therapeutics Corp. operates as a clinical-stage biotechnology company that specializes in immunotherapy for advanced breast cancer. It is advancing its targeted immunotherapy program by conducting a Phase I/IIA clinical trial with Bria-IMT in combination with an immune checkpoint inhibitor and a companion diagnostic test, BriaDx, to identify patients to benefit from Bria-IMT. The company was founded by Charles L. Wiseman and Isaac B. Maresky on July 26, 2006 and is headquartered in West Vancouver, Canada.
Head office | Canada |
CEO | William Williams |
Employees | 18 |
Founded | 2006 |
Website | www.briacell.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.